TY - JOUR
T1 - Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up
AU - Huynh, Kevin A.
AU - Coopmans, Eva C.
AU - Najafabadi, Amir H. Z.
AU - Dirven, Linda
AU - Peerdeman, Saskia M.
AU - Biermasz, Nienke R.
AU - Verstegen, Marco J. T.
AU - van Furth, Wouter R.
AU - the Dutch Meningioma Consortium
AU - Boele, Florien W.
AU - Klein, Martin
AU - Koekkoek, Johan
AU - Lagerwaard, Frank
AU - van der Meer, Pim B.
AU - Taphoorn, Martin J. B.
AU - Moojen, Wouter A.
AU - Reijneveld, Jaap C.
N1 - Funding Information: Kevin A. Huynh was supported by a personal MD/PhD grant from the Leiden University Medical Center. The other authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Publisher Copyright: © 2023, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Purpose: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients’ functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. Methods: A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients ‘functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. Results: We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262–€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. Conclusion: In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients’ HRQoL and needs could be beneficial in reducing disease burden and functional recovery.
AB - Purpose: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients’ functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. Methods: A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients ‘functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. Results: We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262–€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. Conclusion: In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients’ HRQoL and needs could be beneficial in reducing disease burden and functional recovery.
KW - Costs
KW - Health-related quality of life
KW - Healthcare utilization
KW - Meningioma
KW - Patient-reported outcome
KW - Value-based healthcare
UR - http://www.scopus.com/inward/record.url?scp=85146018646&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s11060-022-04223-0
DO - https://doi.org/10.1007/s11060-022-04223-0
M3 - Article
C2 - 36626042
SN - 0167-594X
VL - 161
SP - 357
EP - 370
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 2
ER -